���构特征与受体作用机制 — Hands-On Walkthrough

By Editorial Desk · published 2025-11-05 · last reviewed 2025-12-03 · Faq

This is a working overview of incretin hormone, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-12-03 and is reviewed periodically as new material appears.

结构特征与受体作用机制

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。

Peptide Background and Receptor Mechanism

The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.

Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.

Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.

Semaglutide at a glance

Background and Drug Class

Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.

Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.

Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.

Related pages on this site

• Simple checklist
• Robust toolkit
• Material analysis
• Robust casebook
• Modern analysis
• Scheduled casebook
• Scheduled toolkit
• Balanced playbook

Background and Molecular Profile

Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.

Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.

The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.

Mechanism and Pharmacological Class

Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.

Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.

The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.

Handling, Storage, And Analytical Checks

Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.

Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.

Notes from published material

On 4 November, Chinese Foreign Ministry spokeswoman Mao Ning defended China's growing cooperation with Venezuela, saying it "constitutes normal cooperation between sovereign states" and is "not directed against any third party". She was quoted as saying "China supports strengthened international cooperation to combat transnational crime and opposes the use or threat of force in international relations." She added that China "opposes any attempt to undermine peace and stability in Latin America and the Caribbean, as well as unilateral coercive actions against foreign vessels that exceed reasonable and necessary limits." China urged the US to "carry out regular judicial and law enforcement cooperation through bilateral and multilateral legal frameworks". The Iranian ambassador to the UN in Geneva condemned the attack as illegal under international law. Journalist Katy Balls wrote that the strikes were "a response to Beijing's fast-growing influence in Latin America." In November 2025, Pope Leo XIV noted that the strikes were gradually nearing Venezuela's coastline and stated that they were only "increasing tension"; he called for the United States and Venezuela to "seek dialogue".

== Biosynthesis == Its complete biosynthetic pathway includes glycolysis, the tricarboxylic acid (TCA) or citric acid cycle (Krebs cycle), and the aspartate metabolic pathway. It forms by two reductions of aspartic acid via the intermediacy of aspartate semialdehyde. Specifically, the enzyme homoserine dehydrogenase, in association with NADPH, catalyzes a reversible reaction that interconverts L-aspartate-4-semialdehyde to L-homoserine. Homoserine kinase and homoserine O-succinyltransferase convert homoserine to phosphohomoserine and O-succinyl homoserine, respectively. Homoserine is produced from aspartate via the intermediate aspartate-4-semialdehyde, which is produced from β-phosphoaspartate. By the action of homoserine dehydrogenases, the semialdehyde is converted to homoserine.

==== Limitations ==== Studying the exact functions mediated by KOR is limited by the non-selectivity and signaling biases of the compounds used in the research and naturally occurring in the human body. Dynorphin peptides, endogenous agonists of KOR, especially big dynorphin, are direct complex modulators of the NMDA receptor. Certain dynorphin peptides also have affinity for the MOR and DOR and influence other pathways that are not directly coupled to KOR. KOR activation in the context of in vivo stress responses could be biased for β-arrestin2 and other pathways related to dysphoria due to the presence of corticotropin-releasing hormone (CRF). Salvinorin A as well as other KOR agonists have been found to possess properties such as dopamine D2 receptor agonism with lower, but non-negligible affinity and potency. Salvinorin A is a balanced G protein and β-arrestin2 agonist.

=== Glucocorticoid activity === Progesterone is a partial agonist of the glucocorticoid receptor (GR). It has about 35% of the affinity of dexamethasone, a corticosteroid, for the human GR, and about 3 to 11% of the affinity of dexamethasone for the rat GR. However, progesterone appears to show weak or no glucocorticoid activity and no antiglucocorticoid activity in vitro and in animals. Nonetheless, progesterone has been found to upregulate the thrombin receptor in vascular smooth muscle cells in vitro, a glucocorticoid effect, and this could have clinical relevance in relation to risk of blood clots.

Sources: en.wikipedia.org

Further detail

2006: Chilean biochemist Cecilia Hidalgo Tapia became the first woman to receive the Chilean National Prize for Natural Sciences. 2006: Chinese-American biochemist Yizhi Jane Tao led a team of researchers to become the first to map the atomic structure of Influenza A, contributing to antiviral research. 2006: Parasitologist Susan Lim became the first Malaysian scientist elected to the International Commission on Zoological Nomenclature. 2006: Merieme Chadid became the first Moroccan person and the first female astronomer to travel to Antarctica, leading an international team of scientists in the installation of a major observatory in the South Pole. 2006: American computer scientist Frances E. Allen won the Turing Award for "pioneering contributions to the theory and practice of optimizing compiler techniques that laid the foundation for modern optimizing compilers and automatic parallel execution". She was the first woman to win the award. 2006: Israeli crystallographer Ada E. Yonath became the first woman awarded the Wolf Prize in Chemistry for "ingenious structural discoveries of the ribosomal machinery of peptide-bond formation and the light-driven primary processes in photosynthesis." 2006: Canadian-American computer scientist Maria Klawe became the president of Harvey Mudd College. 2007: Using satellite imagery, Egyptian geomorphologist Eman Ghoneim discovered traces of an 11,000-year-old mega lake in the Sahara Desert. The discovery shed light on the origins of the largest modern groundwater reservoir in the world.

==== Samoa ==== Glass noodles were introduced to Samoa by Cantonese agricultural workers in the early 1900s, where they became known as "lialia" (from Samoan: liaʻi meaning "to twirl" as in the method of twirling the noodles around chopsticks when eating). A popular dish called sapasui (transliteration of the Cantonese 雜碎 zaap soei) is common fare at social gatherings. Sapasui, a soupy dish of boiled glass noodles mixed with braised pork, beef, or chicken, and chopped vegetables, is akin to Hawaiian "long rice".

=== Sequestrate species === The description of Russula was changed in 2007 when molecular analysis revealed that several sequestrate species formerly classified in Macowanites (syn. Elasmomyces) were shown to lie within Russula. The type species of Macowanites, Macowanites agaricinus, was transferred and several new species were added: Russula albidoflava, R. albobrunnea, R. brunneonigra, R. galbana, R. pumicoidea, R. reddellii, R. sinuata, and R. variispora. The genus names Gymnomyces and Martellia, formerly used for sequestrate species, are now accepted synonyms of Russula, The genus Cystangium is also probably a synonym of Russula but is still in use.

Sources: en.wikipedia.org

Frequently asked questions